Differentiation Syndrome; acute myeloid leukemia; absolute neutrophil count; treatment-emergent adverse event; KMT2A, lysine methyltransferase 2A; integrated summary of safety; Revuforg; Revuforj; dose modification; AUGMENT 101; adverse reactions; adverse event; safety; AE; adverse event management; adverse event; safety; adverse reactions; revumenib; black box warning; Dose modification; dose reduction; dose interruption;mechanism of action; revumenib MOA; revumenib mechanism of action; revumenib action; revumenib mechanism; KMT2ar mechanism; revumenib MOA in KMT2ar; MOA in KMT2ar; MOA in KMT2ar AML; MOA in KMT2ar ALL; MOA in KMT2ar acute leukemia; Revuforg; Revuforj; KMT2A translocation;mechanism of action; revumenib MOA; revumenib mechanism of action; revumenib action; revumenib mechanism; KMT2ar mechanism; revumenib MOA in KMT2ar; MOA in KMT2ar; MOA in KMT2ar AML; MOA in KMT2ar ALL; MOA in KMT2ar acute leukemia; Revuforg; Revuforj; KMT2A translocation;mechanism of action; revumenib MOA; revumenib mechanism of action; revumenib action; revumenib mechanism; AUGMENT 101; Adverse Event; Dose Modification; dose limiting toxicity; treatment-emergent adverse event; safety; Revuforg; Revuforj; KMT2A, lysine methyltransferase 2A; adverse reactions; adverse event management; adverse event; AE; revumenib; QTC; QT; Dose modification; dose reduction; dose interruption; Pharmacokinetics; pk; poppk; efficacy response